TNF and infection: In total, 18 cohorts evaluated the risk of serious infections,11,12,15,17,20,28,29,30,31,36,38,40,48,51,52 17 cohorts examined the risk of cancer,20,23,26,28,34,36,37,38,39,40,41,42,45 29 cohorts assessed the risk of MACEs,12,13,16,18,19,22,24,25,27,28,31,32,33,36,37,39,41,44,46,47,48,49,50,51,52 and 16 cohorts compared the risk of VTE12,14,18,21,22,32,36,37,41,43,49,50,51,52 with JAK inhibitors vs TNF antagonists.